Novartis reports positive phase 3 data on ianalumab for Sjögren’s
Novartis reported positive long-term phase 3 data for ianalumab in Sjögren’s disease, showing improved disease activity and a favorable safety profile. The FDA granted Breakthrough Therapy Designation in January, with a decision expected this year. Ianalumab is also being investigated for other autoimmune diseases. Novartis aims to address the unmet need for disease-modifying treatments in Sjögren’s.
How this was made

The 30-second read
Why it matters
The NEPTUNUS extension data show continued deepening of systemic disease activity reductions through week 108 with a safety profile comparable to placebo, supporting the clinical case for ianalumab ahead of an FDA decision expected this year.
Market read
Traders may reassess ianalumab’s durability and safety profile, which can shift probability-weighted outcomes for regulatory approval in Sjögren’s.
What to watch
Regulatory impact depends on how these extension results map to the primary regulatory package and whether the FDA focuses on week 48 endpoints versus longer-term durability; also, the competitive context includes Amgen’s separate Phase 3 readout in the same disease.
Background
Sjögren’s disease lacks an FDA-approved disease-modifying therapy, and dry eye is a hallmark feature; ianalumab targets BAFF-R to reduce B-cell driven inflammation.
Ticker impact
Novartis reports positive long-term Phase 3 NEPTUNUS extension results for ianalumab in Sjögren’s, including week 108 EULAR ESSDAI reductions and safety comparable to placebo.
Likely modest upward bias as investors price improved efficacy durability and manageable safety, while awaiting the FDA review outcome.
The article provides specific efficacy durability through week 108, notes no new safety signals, and reiterates FDA decision timing, which can move biotech sentiment even without an approval or guidance change.
Market effects
Reinforces competitive momentum in B-cell targeted autoimmune therapeutics for Sjögren’s, potentially raising the bar for efficacy durability and safety in the class.
Primarily impacts European large-cap biotech sentiment (Switzerland/Europe) tied to global autoimmune pipeline expectations.
Could influence global biotech risk appetite for autoimmune immunology assets as investors compare Phase 3 durability readouts across sponsors.
Counterpoint
Despite positive long-term trends, the article says no significant differences were seen at week 48 for key response endpoints and highlights injection-site/systemic reactions, which may temper enthusiasm.
Key entities
- companyNovartis
Sponsor reporting positive Phase 3 NEPTUNUS extension results for ianalumab in Sjögren’s.
- drugianalumab
Investigational fully human monoclonal antibody targeting BAFF-R, delivered subcutaneously.
- clinical_trialNEPTUNUS extension study
Phase 3 extension presenting long-term efficacy and safety through week 108.
- regulatorFDA
Regulatory authority reviewing ianalumab, with a decision expected this year per the company.



